ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,142.00
-0.13%
S&P ASX All Technology
3,417.00
0.40%
Brent Oil
74.615
1.19%
US Dollar vs AUD
1.45292
-0.71%
Bitcoin
63,834.30
0.81%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Poseida Therapeutics Inc (PSTX)

  7. Poseida Therapeutics Inc (PSTX) News

PSTX

Poseida Therapeutics (PSTX)

Poseida Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:PSTX
DateTimeSourceHeadlineSymbolCompany
16/09/202422:00PR Newswire (US)Poseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
05/09/202423:00PR Newswire (US)Poseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
05/09/202406:05PR Newswire (US)Poseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
30/08/202406:05PR Newswire (US)Poseida Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:PSTXPoseida Therapeutics Inc
15/08/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
06/08/202406:33Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:PSTXPoseida Therapeutics Inc
06/08/202406:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
06/08/202406:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
06/08/202406:05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Second Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
02/07/202406:05PR Newswire (US)Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy ForumNASDAQ:PSTXPoseida Therapeutics Inc
19/06/202406:15Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
19/06/202406:12Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PSTXPoseida Therapeutics Inc
19/06/202406:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
04/06/202406:05PR Newswire (US)Poseida Therapeutics Announces Virtual 2024 Annual Meeting of StockholdersNASDAQ:PSTXPoseida Therapeutics Inc
15/05/202406:11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PSTXPoseida Therapeutics Inc
15/05/202406:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PSTXPoseida Therapeutics Inc
15/05/202406:05PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024NASDAQ:PSTXPoseida Therapeutics Inc
09/05/202423:00PR Newswire (US)Poseida Highlights Strong Progress on Its Genetic Medicine Programs at the American Society for Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
06/05/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:PSTXPoseida Therapeutics Inc
02/05/202411:30PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
02/05/202405:25AllPennyStocks.comBiotech Soars on Research Collaboration And License Agreement ReleaseNASDAQ:PSTXPoseida Therapeutics Inc
01/05/202423:00PR Newswire (US)Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in OncologyNASDAQ:PSTXPoseida Therapeutics Inc
18/04/202422:00PR Newswire (US)Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual MeetingNASDAQ:PSTXPoseida Therapeutics Inc
17/04/202423:00PR Newswire (US)Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline FocusNASDAQ:PSTXPoseida Therapeutics Inc
09/04/202402:00PR Newswire (US)Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
02/04/202407:05PR Newswire (US)Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PSTXPoseida Therapeutics Inc
26/03/202407:05PR Newswire (US)Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical OfficerNASDAQ:PSTXPoseida Therapeutics Inc
20/03/202407:05PR Newswire (US)Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual ConferenceNASDAQ:PSTXPoseida Therapeutics Inc
14/03/202407:05PR Newswire (US)Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple MyelomaNASDAQ:PSTXPoseida Therapeutics Inc
08/03/202408:07PR Newswire (US)Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023NASDAQ:PSTXPoseida Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:PSTX

Your Recent History

ASX
NAB
National Australia Bank
SPI
SP500
S&P 500
NYSE
VZ
Verizon Communications
NYSE
JPM
JP Morgan Chase
ASX
WOW
Woolworths
ASX
WDC
Westfield
ASX
ORG
Origin Energy
COIN
SOLUSD
Solana
PM
XAUUSD
Gold vs US Dollar
COIN
BTCUSD
Bitcoin
NYSE
XOM
Exxon Mobil
COIN
XRPUSD
Ripple
NASDAQ
AMZN
Amazon.com
FX
AUDJPY
AUD vs Yen
ASX
AMP
AMP
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved